Boehringer Ingelheim Product Nerandomilast Meets Primary Endpoint in Phase III Study in Progressive Pulmonary Fibrosis 

Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in FVC (mL) at week 52...